Medical policy: Hematopoietic Cell Transplantation for Acute Myeloid Leukemia

Policy number: MP 9.040

Effective date: 5/1/2026

Policy

Allogeneic hematopoietic cell transplantation (HCT) using a myeloablative conditioning regimen may be considered medically necessary to treat:

• Poor- to intermediate-risk acute myeloid leukemia (AML) in first complete remission (CR1) (see Policy Guidelines for risk stratification); or
• AML that is refractory to standard induction chemotherapy, but can be brought into CR with intensified induction chemotherapy; or
• AML that relapses following chemotherapy-induced CR1 but can be brought into CR2 or beyond with intensified induction chemotherapy; or
• AML in individuals who have relapsed following a prior autologous HCT, but can be brought into CR with intensified induction chemotherapy and are medically able to tolerate the procedure.

Allogeneic HCT using a reduced-intensity conditioning regimen may be considered medically necessary as a treatment of AML in individuals who are in complete marrow and extramedullary remission (CR1 or beyond) and who for medical reasons would be unable to tolerate a myeloablative conditioning regimen (see Policy Guidelines).

Autologous HCT may be considered medically necessary to treat AML in CR1 or beyond, or relapsed AML, if responsive to intensified induction chemotherapy in individuals who are not candidates for allogeneic HCT.

Allogeneic and autologous HCT are investigational in individuals not meeting any of the above criteria, as there is insufficient evidence to support a general conclusion concerning the health outcomes or benefits associated with this procedure.

Policy guidelines

Primary refractory acute myeloid leukemia (AML) is defined as leukemia that does not achieve a complete remission after conventionally dosed (non-marow ablative) chemotherapy.

In the French-American-British criteria, the classification of AML is based solely on morphology as determined by the degree of differentiation along different cell lines and the extent of cell maturation.

Clinical features that predict poor outcomes of AML therapy include, but are not limited to, the following:

• Treatment-related AML (secondary to prior chemotherapy and/or radiotherapy for another malignancy)
• AML with antecedent hematologic disease (e.g., myelodysplasia)
• Presence of circulating blasts at the time of diagnosis
• Difficulty in obtaining first complete remission with standard chemotherapy
• Leukemias with monocytic differentiation (French-American-British classification M4 or M5)

The newly preferred World Health Organization (WHO) classification of AML incorporates and interrelates morphology, cytogenetics, molecular genetics, and immunologic markers in an attempt to construct a classification that is universally applicable and prognostically valid. The WHO system was adopted by the National Comprehensive Cancer Network (NCCN) to estimate individual prognosis to guide management, as shown in Table PG1.

Table PG1. Risk status of AML based on genetic factors

AML: acute myeloid leukemia; ITD: internal tandem duplication.

The relative importance of cytogenetic and molecular abnormalities in determining prognosis and guiding therapy is under investigation.

The ideal allogeneic donors are human leukocyte antigen (HLA)–identical siblings, matched at the HLA-A, -B, and -DR (antigen-D related) loci on each arm of chromosome 6. Related donors mismatched at one locus are also considered suitable donors. A matched, unrelated donor identified through the National Marrow Donor Registry is typically the next option considered.

Recently, there has been interest in haploidentical donors, typically a parent or a child of the individual for which there is usually sharing of only 3 of the 6 major histocompatibility antigens. Most individuals will have such a donor; however, the risk of graft-versus-host disease and overall morbidity with these donors is generally higher than with matched donors.

Cross-references

• MP 9.001 Placental/Umbilical Cord Blood as a Source of Stem Cells

Product variations

This policy is only applicable to certain programs and products administered by Capital Blue Cross and subject to benefit variations. Please see additional information below.

FEP PPO - Refer to the FEP medical policy manual. The FEP medical policy manual can be found at FEP Medical Policy Manual.

Description/background

Acute myeloid leukemia

Acute myeloid leukemia (AML) refers to leukemias that arise from a myeloid precursor in the bone marrow. There is a high incidence of relapse, which has prompted research into various post-remission strategies using either allogeneic (allo-) or autologous hematopoietic cell transplantation (HCT). Hematopoietic cell transplantation refers to a procedure that infuses hematopoietic stem cells to restore bone marrow function in individuals with cancer who receive bone marrow-toxic doses of drugs with or without whole-body radiotherapy.

Treatment

Complete remission of AML can be achieved initially using induction therapy, consisting of conventional doses of combination chemotherapy. A complete response is achieved in 60% to 80% of adults younger than 60 years of age and in 40% to 60% in individuals older than 60 years of age. However, the high incidence of disease relapse has prompted research into a variety of post-remission (consolidation) strategies using high-dose chemotherapy with autologous HCT or high-dose or reduced-intensity chemotherapy with allogeneic HCT (allo-HCT).

The 2 treatments, autologous HCT and allo-HCT, represent 2 different strategies. The first, autologous HCT, is a “rescue,” but not a therapeutic procedure; the second, allo-HCT, is a “rescue” plus a therapeutic procedure.

Hematopoietic cell transplantation

HCT is a procedure in which hematopoietic stem cells are intravenously infused to restore bone marrow and immune function in cancer patients who receive bone marrow-toxic doses of cytotoxic drugs with or without whole-body radiotherapy. Hematopoietic stem cells may be obtained from the transplant recipient (autologous HCT) or a donor (allo-HCT). These cells can be harvested from bone marrow, peripheral blood, or umbilical cord blood shortly after delivery of neonates. Cord blood is discussed in detail in evidence review MP 9.001.

Immunologic compatibility between infused hematopoietic stem cells and the recipient is not an issue in autologous HCT. In allo-HCT, immunologic compatibility between donor and patient is a critical factor for achieving a successful outcome. Compatibility is established by typing of human leukocyte antigens (HLAs) using cellular, serologic, or molecular techniques. HLA refers to the gene complex expressed at the HLA-A, -B, and -DR (antigen-D related) loci on each arm of chromosome 6. An acceptable donor will match the patient at all or most of the HLA loci.

Conventional conditioning for HCT

The conventional (“classic”) practice of allo-HCT involves administration of cytotoxic agents (e.g., cyclophosphamide, busulfan) with or without total body irradiation at doses sufficient to cause bone marrow ablation in the recipient. The beneficial treatment effect of this procedure is due to a combination of initial eradication of malignant cells and subsequent graft-versus-malignancy (GVM) effect mediated by non-self immunologic effector cells. While the slower GVM effect is considered the potentially curative component, it may be overwhelmed by existing disease in the absence of pretransplant conditioning.

Intense conditioning regimens are limited to patients who are sufficiently medically fit to tolerate extensive damage of other tissues such as end-organ damage or failure caused by cytotoxic drugs. Subsequent to graft infusion in allo-HCT, immunosuppressant drugs are required to minimize graft rejection and graft-versus-host disease (GVHD), which increases susceptibility to opportunistic infections.

The success of autologous HCT is predicated on the potential of cytotoxic chemotherapy, with or without radiotherapy, to eradicate cancerous cells from the blood and bone marrow. This permits subsequent engraftment and repopulation of bone marrow with hematopoietic stem cells obtained from the patient before undergoing bone marrow ablation. Therefore, autologous HCT is typically performed as consolidation therapy when the patient’s disease is in complete remission. Patients who undergo autologous HCT are susceptible to chemotherapy-related toxicities and opportunistic infections before engraftment, but not GVHD.

Reduced-intensity conditioning for allo-HCT

Reduced-intensity conditioning (RIC) refers to the pretransplant use of lower doses of cytotoxic drugs or less intense regimens of radiotherapy than are used in traditional full-dose myeloablative conditioning (MAC) treatments. Although the definition of RIC is variable, with numerous versions employed, all regimens seek to balance the competing aspects of relapse and non-relapse mortality.

The goal of RIC is to reduce morbidity and non-relapse mortality during the period in which the beneficial graft-versus-malignancy effect of allogeneic transplantation develops. Reduced-intensity conditioning regimens range from nearly total myeloablative to minimally myeloablative with lymphoablation, with intensity tailored to specific diseases and patient condition. Patients who undergo RIC with allo-HCT initially demonstrate donor cell engraftment and bone marrow mixed chimerism. Most will subsequently convert to full-donor chimerism. In this review, the term reduced-intensity conditioning will refer to all conditioning regimens intended to be nonmyeloablative.

A 2015 review in the New England Journal of Medicine summarized advances in the classification of AML, the genomics of AML and prognostic factors, and current and new treatments. The National Comprehensive Cancer Network guidelines provide updated information on genetic markers for risk stratification, and additional recent reviews summarize information on novel therapies for AML.

Regulatory status

The U.S. Food and Drug Administration regulates human cells and tissues intended for implantation, transplantation, or infusion through the Center for Biologics Evaluation and Research, under Code of Federal Regulation, Title 21, parts 1270 and 1271. Hematopoietic stem cells are included in these regulations.

Rationale

Summary of evidence

For individuals who have cytogenetic or molecular intermediate- or poor-risk AML in first complete remission (CR1) who receive allo-HCT with myeloablative conditioning, the evidence includes systematic reviews, randomized controlled trials, and matched cohort studies. Relevant outcomes are overall survival, disease-specific survival, and treatment-related mortality and morbidity. The majority of the evidence suggests that allo-HCT is better at improving overall and disease-free survival than consolidation chemotherapy. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have AML refractory to standard induction chemotherapy who receive allo-HCT with myeloablative conditioning, the evidence includes retrospective data comparing patients entered into phase 3 trials and registry databases. The evidence suggests that allo-HCT improves overall survival and disease-specific survival in patients refractory to induction chemotherapy better than conventional chemotherapy. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have AML who relapse after standard induction chemotherapy-induced CR1 who receive allo-HCT or autologous HCT with MAC, the evidence includes retrospective studies and registry data. Relevant outcomes are overall survival and disease-specific survival. The evidence shows that allo-HCT improves survival outcomes compared with conventional chemotherapy. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have cytogenetic or molecular intermediate- or poor-risk AML in CR1 and for medical reasons cannot tolerate MAC who receive allo-HCT with reduced-intensity conditioning (RIC), the evidence includes randomized controlled trials, meta-analyses, and other comparative studies. The evidence indicates that RIC results are similar to MAC in relapse mortality, relapse, and overall survival, although some trials were stopped prematurely. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have AML in CR1 or beyond without a suitable allo-HCT donor who receive autologous HCT, the evidence includes prospective cohort studies and randomized trials comparing autologous HCT with chemotherapy. Relevant outcomes are overall and disease-free survival. Autologous HCT reduces relapse rates and improves disease-free survival, though overall survival does not differ significantly. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

Definitions

Relapsed refers to patients who have achieved remission but later have decreased numbers of normal blood cells and a return of leukemia in their bone marrow.

Refractory refers to patients who have residual leukemia cells in their bone marrow even after they receive intensive treatment.

Disclaimer

Capital Blue Cross’ medical policies are used to determine coverage for specific medical technologies, procedures, equipment, and services. These medical policies do not constitute medical advice and are subject to change as permitted by law or applicable clinical evidence from independent treatment guidelines. Treating providers are solely responsible for medical advice and treatment of members. These policies are not a guarantee of coverage or payment. Payment of claims is subject to a determination regarding the member’s benefit program and eligibility on the date of service, and a determination that the services are medically necessary and appropriate. Final processing of a claim is based upon the terms of contract that applies to the member’s benefit program, including benefit limitations and exclusions. If a provider or a member has a question concerning this medical policy, please contact Capital Blue Cross’ Provider Services or Member Services.

Coding information

Note: This list of codes may not be all-inclusive, and codes are subject to change at any time. The identification of a code in this section does not denote coverage as coverage is determined by the terms of member benefit information. In addition, not all covered services are eligible for separate reimbursement.

Covered when medically necessary

References

1. Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. Sep 17 2015;373(12):1136-52. PMID 26376137.
2. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: acute myeloid leukemia. Version 3.2024. Updated May 17, 2024.
3. Blum WG, Mims AS. Treating acute myeloid leukemia in the modern era: a primer. Cancer. Nov 01 2020;126(21):4668-4677. PMID 32763757.
4. Koeing K, Mims A, Levis MJ, et al. The changing landscape of treatment in acute myeloid leukemia. Am Soc Clin Oncol Educ Book. Mar 2020;40:1-12. PMID 32239961.
5. Masner S, Mansour R, Devarakonda SS, et al. Predictors of survival in acute myeloid leukemia by treatment modality. Anticancer Res. Apr 2016;36(4):1719-27. PMID 27069151.
6. Masetti R, Muratore E, Gori D, et al. Allogeneic stem cell transplantation for pediatric acute myeloid leukemia in first complete remission: a meta-analysis. Ann Hematol. Nov 2022;101(11):2497-2505. PMID 36038660.
7. Li D, Wang L, Zhu H, et al. Efficacy of allogeneic hematopoietic stem cell transplantation in intermediate-risk acute myeloid leukemia adult patients in first complete remission: a meta-analysis of prospective studies. PLoS One. 2015;10(7):e0132620. PMID 26197471.
8. Koreth J, Schlenk RF, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. Jun 10 2009;301(22):2349-61. PMID 19509382.
9. Yanada M, Matsuo K, Emi N, et al. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk of acute myeloid leukemia in first disease remission: a meta-analysis. Cancer. Apr 15 2005;103(8):1652-8. PMID 15742336.
10. Baer MR, Greer JP. Acute myeloid leukemia in adults. In: Greer JP, Foerster J, Rodgers GM, et al., eds. Wintrobe’s Clinical Hematology (12th ed.). Vol 2. Philadelphia, PA: Lippincott Williams & Wilkins; 2009:1843-1888.
11. Hamadani M, Awan FT, Copelan EA. Hematopoietic stem cell transplantation in adults with acute myeloid leukemia. Biol Blood Marrow Transplant. May 2008;14(5):556-67. PMID 18410896.
12. Deschler B, de Witte T, Mertelsmann R, et al. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica. Nov 2006;91(11):1513-22. PMID 17082009.
13. Craddock CF. Full-intensity and reduced-intensity allogeneic stem cell transplantation in AML. Bone Marrow Transplant. Mar 2008;41(5):415-23. PMID 18209726.
14. Cornelissen JJ, van Putten WLJ, Verdonck LF, et al. Results of the HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood. May 2007;109(9):3658-66. PMID 17213292.
15. Mrózek K, Bloomfield CD. Chromosomal aberrations, gene mutations and expression changes, and prognosis in adult acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2006:169-77. PMID 17244057.
16. Paschka P, Marcucci G, Ruppert AS, et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B study. J Clin Oncol. Aug 20 2006;24(24):3904-11. PMID 16921041.
17. Schlenk RF, Döhner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. May 08 2008;358(18):1909-18. PMID 18450602.
18. Buckley SA, Wood BL, Othus M, et al. Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Haematologica. May 2017;102(5):865-873. PMID 28269563.
19. Bornhauser M, Schliemann C, Schetelig J, et al. Allogeneic hematopoietic cell transplantation vs standard consolidation chemotherapy in patients with intermediate-risk acute myeloid leukemia: a randomized clinical trial. JAMA Oncol. Apr 01 2023;9(4):519-526. PMID 36575706.
20. Stelljes M, Krug U, Beelen DW, et al. Allogeneic transplantation versus chemotherapy as postremission therapy for acute myeloid leukemia: a prospective matched pairs analysis. J Clin Oncol. Feb 01 2014;32(4):288-96. PMID 24366930.
21. Heidrich K, Thiede C, Schäfer-Eckart K, et al. Allogeneic hematopoietic cell transplantation in intermediate-risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations. Ann Oncol. Nov 01 2017;28(11):2793-2798. PMID 28945881.
22. Begna KH, Kittang AO, Gangat N, et al. European LeukemiaNet-defined primary refractory acute myeloid leukemia: value of allogeneic hematopoietic stem cell transplantation and overall response. Blood Cancer J. Jan 17 2022;12(1):7. PMID 35039473.
23. Wang ZY, Gao WH, Zhao HJ, et al. Chemotherapy or allogeneic stem cell transplantation as salvage therapy for patients with refractory acute myeloid leukemia: a multicenter analysis. Acta Haematol. 2022;145(4):419-429. PMID 35233903.
24. Stone RM, O’Donnell MR, Sekeres MA. Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2004:98-117. PMID 15561679.
25. Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol. Mar 01 2005;23(9):1969-78. PMID 15632409.
26. Fráter JL, Guban S, Doucette S, et al. Characteristics predicting outcomes of allogeneic stem-cell transplantation in relapsed acute myelogenous leukemia. Curr Oncol. Apr 2017;24(2):e123-e130. PMID 28499935.
27. Breems DA, Boender P, Ackermann G, et al. Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation with acute myeloid leukemia. Cancer Control. Oct 2010;17(4):237-45. PMID 20976492.
28. Olianski DL, Appelbaum FR, Cassileth PA, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant. Feb 2008;14(2):137-80. PMID 18215777.
29. Blaise D, Vey N, Faucher C, et al. Current status of reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica. Apr 2007;92(4):533-41. PMID 17488664.
30. Huisman C, Meijer E, Petersen EJ, et al. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemias of older than 40 years. Biol Blood Marrow Transplant. Feb 2008;14(2):181-6. PMID 18215778.
31. Valkarel D, Marino R, Caballero D, et al. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia. Curr Opin Oncol. Nov 2007;19(6):660-6. PMID 17906468.
32. Valcarcel D, Martino R, Caballero D, et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest long-term prognostic factor. J Clin Oncol. Feb 01 2008;26(4):577-84. PMID 18086801.
33. Gyurkocza B, Storb R, Storer BE, et al. Nonmyeloablative allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia. J Clin Oncol. Jun 10 2010;28(17):2859-67. PMID 20439626.
34. McClune BL, Weisdorf DJ, Petersen ET, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol. Apr 10 2010;28(11):1878-87. PMID 20212255.
35. Peffault de Latour R, Porcher R, Dalle JH, et al. Allogeneic hematopoietic stem cell transplantation in Fanconi anemia: the European Group for Blood and Marrow Transplantation experience. Blood. Dec 19 2013;122(26):4273-82. PMID 24444640.
36. Hamdani A, Almagahani K, Jahami M, et al. Non-TBI hematopoietic stem cell transplantation in pediatric AML patients: a single-center experience. J Pediatr Hematol Oncol. Aug 2013;35(6):e239-45. PMID 23042019.
37. Lim Z, Brand R, Martino R, et al. Allogeneic hematopoietic stem-cell transplantation for patients 50 years or older with myelodysplastic syndromes or secondary acute myeloid leukemia. J Clin Oncol. Jan 20 2010;28(3):405-11. PMID 20008642.
38. Pemmaraju N, Tanaka MF, Ravandi F, et al. Outcomes in patients with relapsed or refractory acute myeloid leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk. Aug 2013;13(4):485-92. PMID 23769669.
39. Song Y, Yin Z, Ding J, et al. Reduced intensity conditioning followed by allogeneic hematopoietic stem cell transplantation is a good choice for acute myeloid leukemia and myelodysplastic syndrome: a meta-analysis of randomized controlled trials. Front Oncol. 2021;11:700727. PMID 34692485.
40. Rashidi A, Ebadi M, Collett G4, et al. Outcomes of allogeneic stem cell transplantation in elderly patients with acute myeloid leukemia: a systematic review and meta-analysis. Biol Blood Marrow Transplant. Apr 2016;22(4):661-657. PMID 26529178.
41. Abdul Wahid SF, Ismail NA, Mohd-Idris MR, et al. Comparison of reduced-intensity and myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia and acute lymphoblastic leukemia: a meta-analysis. Stem Cells Dev. Nov 01 2014;23(21):2535-52. PMID 25072307.
42. Bornhauser M, Kienast J, Trenschel R, et al. Reduced-intensity conditioning versus standard conditioning before allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia in first complete remission: a prospective, open-label randomized phase 3 trial. Lancet Oncol. Oct 2012;13(10):1035-44. PMID 22959335.
43. Scherwath A, Schirmer L, Kruse M, et al. Cognitive functioning in allogeneic hematopoietic stem cell transplantation recipients and its medical correlates: a prospective multicenter study. Psychooncology. Jul 2013;22(7):1509-16. PMID 22945857.
44. Shayegi N, Kramer M, Bornhäuser M, et al. The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML. Blood. Jul 04 2013;122(6):83-92. PMID 23656730.
45. Ringdén O, Erkers T, Aschan J, et al. A prospective randomized toxicity study to compare reduced-intensity and myeloablative conditioning in patients with myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation. J Intern Med. Aug 2013;274(2):153-62. PMID 23432209.
46. Russell NH, Hills RK, Thomas A, et al. Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial. Haematologica. Jul 2022;107(7):1518-1527. PMID 34674442.
47. Shimoni A, Labopin M, Savani BN, et al. Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation. J Hematol Oncol. Nov 08 2016;9(1):118. PMID 27821187.
48. Bitan M, He W, Zhang MJ, et al. Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced-intensity and myeloablative regimens. Blood. Mar 06 2014;123(10):1615-20. PMID 24435046.
49. DeVetten AM, Lau W, Blue M, et al. Phase II study of allogeneic transplantation for older AML patients in first complete remission using a reduced-intensity conditioning regimen: results from Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. J Clin Oncol. Dec 10 2015;33(35):4167-75. PMID 26527180.
50. Nathan PC, Sung L, Crump M, et al. Consolidation therapy with autologous bone marrow transplantation in adults with acute myeloid leukemia: a meta-analysis. Natl Cancer Inst J. Oct 07 2004;96(19):1487-96. PMID 14709737.
51. Wang J, Ouyang J, Zhou R, et al. Autologous hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission: a meta-analysis of randomized trials. Acta Haematol. 2010;124(2):61-71. PMID 20616541.
52. Vellenga E, van Putten WL, Ossenkoppele GJ, et al. Autologous peripheral blood stem cell transplantation as consolidation treatment for acute myeloblastic leukemia. Blood. Dec 01 2011;118(23):6037-42. PMID 21951683.
53. Miyamoto T, Iwasaki K, Fujisaki T, et al. Prospective randomized study of post-remission therapy comparing autologous peripheral blood stem cell transplantation versus high-dose cytarabine consolidation for acute myelogenous leukemia in first remission. Int J Hematol. Apr 2018;107(4):468-477. PMID 29243031.
54. Dholaria B, Savani BN, Hamilton BK, et al. Hematopoietic cell transplantation in the treatment of newly diagnosed adult acute myeloid leukemia: an evidence-based review from the American Society of Transplantation and Cellular Therapy. Transplant Cell Ther. Jan 2021;27(1):6-20. PMID 32966881.
55. Majhail NS, Farnia SH, Carpenter PA, et al. Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. Nov 2015;21(11):1863-1869. PMID 26256941.
56. Kanate AS, Majhail NS, Savani BN, et al. Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. Jul 2020;26(7):1247-1256. PMID 32165328.
57. Tarlock K, Sills M, Chewning JH, et al. Hematopoietic cell transplantation in the treatment of pediatric acute myelogenous leukemia and myelodysplastic syndromes: guidelines from the American Society of Transplantation and Cellular Therapy. Transplant Cell Ther. Sep 2022;28(9):530-545. PMID 35717004.
58. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for Stem Cell Transplantation (Formerly 110.8.1) (110.23). 2016. Accessed November 27, 2024.